T

Talkmed Group Ltd
SGX:5G3

Watchlist Manager
Talkmed Group Ltd
SGX:5G3
Watchlist
Price: 0.445 SGD
Market Cap: 590.8m SGD
Have any thoughts about
Talkmed Group Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one 5G3 stock under the Base Case scenario is 0.283 SGD. Compared to the current market price of 0.445 SGD, Talkmed Group Ltd is Overvalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

5G3 Relative Value
Base Case
0.283 SGD
Overvaluation 36%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Valuation Multiples

7.5
P/S
P/S
Price to Sales
7.5
vs History
34
vs Industry
20
Median 3Y
7
Median 5Y
7
Industry
2.3
More Details
21.3
P/E
P/E
Price to Earnings
21.3
vs History
9
vs Industry
31
Median 3Y
18.1
Median 5Y
17.3
Industry
23.2
More Details
17.2
P/OCF
P/OCF
Price to OCF
17.2
vs History
31
vs Industry
29
Median 3Y
15.3
Median 5Y
15.3
Industry
14.3
More Details
17.8
P/FCFE
P/FCFE
Price to FCFE
17.8
vs History
49
vs Industry
29
Median 3Y
17.8
Median 5Y
17.8
Industry
20.1
More Details
7.1
P/B
P/B
Price to Book Value
7.1
vs History
7
vs Industry
12
Median 3Y
5.8
Median 5Y
5.9
Industry
2.2
More Details
6.4
EV/S
EV/S
Enterprise Value to Sales
6.4
vs History
26
vs Industry
21
Median 3Y
6
Median 5Y
6
Industry
2.4
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5
More Details
14.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
14.3
vs History
3
vs Industry
30
Median 3Y
11.8
Median 5Y
11.6
Industry
12.8
More Details
15.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15.5
vs History
4
vs Industry
35
Median 3Y
12.8
Median 5Y
12.6
Industry
17.2
More Details
14.8
EV/OCF
EV/OCF
Enterprise Value to OCF
14.8
vs History
30
vs Industry
33
Median 3Y
13.2
Median 5Y
13.3
Industry
14
More Details
15.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
15.1
vs History
34
vs Industry
32
Median 3Y
14.8
Median 5Y
14.4
Industry
18.2
More Details
36.9
EV/IC
EV/IC
Enterprise Value to IC
36.9
vs History
3
vs Industry
3
Median 3Y
19.5
Median 5Y
19.7
Industry
1.9
More Details

Multiples Across Competitors

5G3 Competitors Multiples
Talkmed Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
Talkmed Group Ltd
SGX:5G3
590.4m SGD 7.5 21.3 14.3 15.5
US
Cigna Group
XMUN:CGN
75B EUR 0.3 25.7 8 10.4
US
Cigna Corp
NYSE:CI
77.2B USD 0.3 25.4 8 10.3
US
CVS Health Corp
NYSE:CVS
56.5B USD 0.2 11.3 9.6 9.6
DE
Fresenius Medical Care AG
XMUN:FME
25.9B EUR 1.3 39.2 10.7 23.1
DE
Fresenius SE & Co KGaA
XETRA:FRE
18.9B EUR 0.9 -49.3 9.3 19
US
Laboratory Corporation of America Holdings
NYSE:LH
19.2B USD 1.5 44.1 13.2 20.3
US
R1 RCM Inc
NASDAQ:RCM
17.7B USD 7.2 -289.7 38.3 99.1
US
Quest Diagnostics Inc
NYSE:DGX
16.9B USD 1.8 20.2 12.2 16.5
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13B EUR 0.7 19.7 6.6 14.3
US
DaVita Inc
NYSE:DVA
12.4B USD 1 14.9 7.8 10.9
P/E Multiple
Earnings Growth PEG
SG
T
Talkmed Group Ltd
SGX:5G3
Average P/E: 24.6
21.3
N/A N/A
US
C
Cigna Group
XMUN:CGN
25.7
25%
1
US
Cigna Corp
NYSE:CI
25.4
25%
1
US
CVS Health Corp
NYSE:CVS
11.3
3%
3.8
DE
Fresenius Medical Care AG
XMUN:FME
39.2
31%
1.3
DE
Fresenius SE & Co KGaA
XETRA:FRE
Negative Multiple: -49.3 N/A N/A
US
Laboratory Corporation of America Holdings
NYSE:LH
44.1
54%
0.8
US
R1 RCM Inc
NASDAQ:RCM
Negative Multiple: -289.7
253%
N/A
US
Quest Diagnostics Inc
NYSE:DGX
20.2
12%
1.7
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
19.7
31%
0.6
US
DaVita Inc
NYSE:DVA
14.9
17%
0.9

See Also

Summary
5G3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
5G3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
5G3 stock valuation using valuation multiples.
Wall Street Estimates
5G3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
5G3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 212,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.